Current Clinical Trials

Trial: AMGEN 20090482
Randomized, Double-Blind Multicenter Study of Denosumab
Compared with Zoledronic Acid in the Treatment of Bone Disease in Subjects
with Newly Diagnosed Multiple Myeloma

Trial: Genentech ML 28257
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive Metastatic Breast Cancer

Trial: AMGEN 20110147 NOLAN
Randomized, phase 2 study to estimate the effect of prophylactic intervention with naproxen or loratidine on bone pain in breast cancer subjects receiving chemotherapy and pegfilgrastim

Trial: AstraZeneca D699BC00001 FALCON
A Randomized, Double-blind, Parallel-group, Multicenter, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant 500mg with anastrozole 1mg as Hormonal treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated with Any Hormonal Therapy

Trial: Novartis BOLERO-6 (CRAD001Y2201)
A three-arm, randomized, open-label, multicenter phase II study investigating  the combination of everolimus with exemestane  versus everolimus alone versus capecitiabine in postmenopausal women with estrogen-receptor positive, HER2-negative, advanced breast cancer after recurrence or progression on letrozole or anastrozole

Trial: AMGEN 20120249
A Randomized, Multi-center Phase 2 Trial of Denosumab in Combination with Chemotherapy as First-line Treatment of Metastatic Non-Small Cell Lung Cancer

Trial: Celgene CC-4047-MM-014
Phase 2, Multicenter, Single-arm, Open label Study of Pomalidomide in Combination with Low-dose Dexamethasone in Subjects with Relapsed or Refractory Mulitple Myeloma Following Lenolidomide Plus Dexamethasone in the Second-line Setting

Website for all clinical trials:

If you require assistance navigating this website, or want more information about our clinical trials, please contact research manager Corilynn Hughes, R.N., B.S.N., O.C.N., at 410-871-6400.